Viewing nowCombinationBonfil Plus D Tablet
Sodium Alendronate Hydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.

MFDS item code 201406151 · Approved 2014.12.30 · Insurance code 649806820
Treatment of osteoporosis in postmenopausal women and men
This medication is used for the treatment of osteoporosis in both postmenopausal women and men.
Take 1 tablet (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with a sufficient amount of water, at least 30 minutes before consuming food, beverages, or other medicines (see “General Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The optimal duration of treatment has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on clinical data from 4 years. The need for continued treatment should be reviewed regularly in all patients receiving bisphosphonates. In patients at low risk of fracture, consider discontinuing treatment after 3~5 years of use. In patients who discontinue treatment, the risk of fracture should be reassessed regularly. Other beverages or foods, including mineral water and barley tea, and medicines may reduce the absorption of alendronate (see “Interactions”). If food is consumed within 30 minutes after taking this medicine or at the same time, the absorption of alendronate into the body may be reduced, decreasing its effect. Take this medicine upon arising in the morning and swallow it with a sufficient amount of water (170∼230 mL) to help the medicine reach the stomach promptly and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking the medicine and until after the first food intake. Do not take this medicine at bedtime or before getting up in the morning. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “General Precautions”). Patients whose dietary intake of calcium and vitamin D is insufficient should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to Be Provided to Patients (4)). Patients at increased risk of vitamin D deficiency (e.g., patients over 70 years of age, nursing home residents, and patients with chronic diseases) may require additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. Once-weekly administration of 1 tablet of this medicine provides one week's supply of vitamin D at 400 IU or 800 IU per day. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the next morning, resume taking it on the originally scheduled day, and then continue taking it regularly once weekly. Do not take 2 tablets on the same day. Use in the elderly (65 years of age and older): No dosage adjustment is necessary. Use in patients with renal impairment: No dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min). However, use of this medicine is not recommended in patients with severe renal impairment (creatinine clearance less than 35 mL/min), as clinical experience is insufficient.
Pediatric and adolescent patients (under 18 years of age): Safety and efficacy in pediatric and adolescent patients have not been established.
This medication may irritate the upper gastrointestinal mucosa, potentially causing esophagitis, esophageal ulcers, and esophageal erosions. If you experience difficulty swallowing, swallowing pain, pain behind the sternum, or heartburn while taking this medication, you should stop taking it immediately and consult a physician. It should be taken with a sufficient amount of water, and you should not lie down for at least 30 minutes after taking it, and the method of administration should be followed precisely. It should not be administered to patients with esophageal conditions that delay esophageal emptying, patients who cannot sit upright for at least 30 minutes, patients with an allergy to this drug's components, or patients with hypocalcemia. Patients with genetic lactose intolerance should also not take this medication. Side effects such as abdominal pain, nausea, dyspepsia, constipation, diarrhea, headache, musculoskeletal pain may occur, although they are mostly mild. Particular caution is needed for patients with a history of gastrointestinal bleeding or ulcers, as the risk of gastrointestinal adverse reactions may increase when used along with aspirin or non-steroidal anti-inflammatory drugs. This medication's absorption may be hindered when taken with calcium supplements or antacids, hence a minimum interval of 30 minutes should be maintained. If you are pregnant or breastfeeding, the decision to administer this medication should be made after consultation with a physician, and it should not be used in children. It is not recommended for patients with severe kidney impairment, and if there is hypocalcemia or vitamin D deficiency, treatment must be administered prior to this medication. Rarely, low-energy fractures may occur with long-term usage, so any unusual symptoms should be discussed immediately with a healthcare professional. This medication must be taken with at least a 30-minute period of sitting upright before the first food intake, and it should not be chewed or sucked. While on this medication, it is recommended to ensure sufficient intake of calcium and vitamin D, avoid weight-bearing exercises, smoking, and excessive drinking. In case of overdose, symptoms of hypocalcemia and gastrointestinal irritation may appear, and do not induce vomiting but seek medical attention immediately. This medication should be kept out of reach of children and should not be transferred to other containers.
Esophagitis, esophageal ulcer, esophageal erosion, esophageal obstruction, esophageal perforation, bleeding, dysphagia, odynophagia, retrosternal pain, heartburn, abdominal pain, nausea, indigestion, constipation, diarrhea, flatulence, acid reflux, esophageal ulcer, vomiting, abdominal distension, gastritis, musculoskeletal (bone, muscle, or joint) pain, muscle cramps, headache, dizziness, taste disorder, rash, erythema, anastomotic ulcer, urticaria, angioedema, myalgia, fatigue, weakness, fever, symptoms of hypocalcemia, peripheral edema, oral pharyngeal ulcer, gastric ulcer, duodenal ulcer, localized jaw necrosis, joint swelling, low-energy fractures of the femoral head and other bones, dizziness, vertigo, itching, hair loss, Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, scleritis, episcleritis, external auditory canal cholesteatoma, nasopharyngitis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it should be stored at room temperature between 1 degree and 30 degrees, preferably in a dark place away from direct light.
White to pale yellow rectangular tablet
4 tablets (4 tablets/PTP X 1)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSodium Alendronate Hydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.
CombinationSodium Alendronate Hydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Sodium Alendronate Hydrate · Cholecalciferol Concentrate Powder
Prescription medication · Combination
Korea Union Pharm Co., Ltd.
CombinationSodium Alendronate Hydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationSodium Alendronate Hydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Shinpoong Pharmaceutical Co., Ltd.
CombinationSodium Alendronate Hydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationSodium Alendronate Hydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationSodium Alendronate Hydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Farm Gen Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.